Shares of Intec Pharma Ltd. (NASDAQ:NTEC) have received an average recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.00.

Several analysts recently issued reports on the stock. Oppenheimer boosted their target price on shares of Intec Pharma from $10.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, September 21st. Roth Capital set a $10.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. CIBC restated an “outperform” rating and set a $15.00 target price (up from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, Maxim Group set a $8.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th.

Shares of Intec Pharma (NASDAQ NTEC) opened at $5.55 on Tuesday. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.

Several institutional investors and hedge funds have recently bought and sold shares of NTEC. Sectoral Asset Management Inc bought a new position in shares of Intec Pharma in the third quarter worth approximately $3,177,000. Pura Vida Investments LLC bought a new position in shares of Intec Pharma in the third quarter worth approximately $895,000. Caxton Corp bought a new position in shares of Intec Pharma in the third quarter worth approximately $681,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Intec Pharma by 5.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 40.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/intec-pharma-ltd-ntec-receives-average-recommendation-of-buy-from-brokerages.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.